Fox Chase Cancer Center News

PHILADELPHIA (January 13, 2025) — Roland Dunbrack, PhD, professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, has been appointed co-leader of the program alongside its current leader, Edna (Eti) Cukierman, PhD.

PHILADELPHIA (December XX, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Qing Chen, MD, PhD, as an Assistant Professor in the Cancer Signaling and Microenvironment Research Program.

PHILADELPHIA (December 7, 2024) — Fox Chase Cancer Center researchers have identified a pretreatment protocol that reduces side effects for the drug motixafortide, which is sold under the brand name Aphexda. The findings, which were presented today at the annual meeting of the American Society of Hematology, has significantly improved the comfort and quality of life for multiple myeloma patients undergoing autologous stem cell transplant.

PHILADELPHIA (December 6, 2024) — Fox Chase Cancer Center and Temple Health physicians and scientists will participate in the presentation and discussion of eight research projects at the American Society of Hematology (ASH) 2024 Annual Meeting, which is being held December 7-10 in San Diego.

PHILADELPHIA (December 3, 2024) — Fox Chase Cancer Center’s Anthony M. Villano, MD, FACS, and Austin D. Williams, MD, MSED, FACS, were named Fellows of the American College of Surgeons (ACS) during a convocation before the organization’s recent Clinical Congress in San Francisco.

PHILADELPHIA (December 3, 2024) The Department of Clinical Genetics at Fox Chase Cancer Center is pleased to announce that genetic counseling, a service that helps individuals and families understand inherited health risks, and clinical services for those considered at high risk for breast cancer are now offered at Temple Health - Chestnut Hill Hospital.

PHILADELPHIA (November 26, 2024) — Fox Chase Cancer Center is pleased to announce that Geneviève Almouzni, PhD, is joining the External Advisory Board of the Cancer Epigenetics Institute (CEI).

PHILADELPHIA (November 25, 2024) — Adjuvant therapy regimens inclusive of chemotherapy were independently associated with improved survival in patients with cT2N0 rectal cancer upstaged to T3N0, according to a new study by researchers at Fox Chase Cancer Center and Temple Health.